Search for: "WYETH LLC" Results 41 - 60 of 220
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
21 May 2015, 1:09 pm by Rebecca Tushnet
   Second, the Court rejected an almost identical pre-approval argument in Wyeth v. [read post]
12 May 2015, 3:26 pm by James Galvin
., Inc. 902619386 UBS Yield Optimization Notes with Contingent Protection linked to General Electric Company 902619394 UBS Yield Optimization Notes with Contingent Protection linked to Exxon Mobil Corp. 902619493 UBS Yield Optimization Notes with Contingent Protection linked to Texas Instruments Inc 902619519 UBS Yield Optimization Notes with Contingent Protection linked to Amgen Inc. 902619527 UBS Yield Optimization Notes with Contingent Protection linked to Goldcorp Inc. 902619535 UBS Yield… [read post]
25 Apr 2015, 11:03 am by Schachtman
The first edition of the Reference Manual on Scientific Evidence [Manual] was published in 1994, a year after the Supreme Court delivered its opinion in Daubert. [read post]
11 Jan 2015, 9:59 pm by Patent Docs
.; Wyeth LLC; Pfizer Pharmaceuticals LLC; PF Prism C.V.; Pfizer Manufacturing Holdings LLC • Defendants: Mylan Inc.; Agila Specialties Private Ltd.; Mylan Pharmaceuticals Inc. [read post]
27 Nov 2014, 5:56 am by Matthew R. Arnold, Esq.
Ex-fund manager Mathew Martoma allegedly received information on disappointing drug trials for products produced by Wyeth LLC and Elan Corp. [read post]
7 Nov 2014, 5:52 am
APP Pharmaceuticals, LLC, 2013 WL 5532767, at *7-8 (D. [read post]
15 Jul 2014, 11:44 pm by Nietzer
I was prosecutor on the Pfizer Wyeth [bribery] case. [read post]
27 Jun 2014, 7:15 pm by Maureen Johnston
Wyeth, LLC; and the plain language of the federal Food, Drug, and Cosmetic Act (“FDCA”)—that federal law does not preempt state tort claims predicated on allegations that a generic drug manufacturer violated the FDCA by failing to immediately implement or otherwise disseminate notice of labeling changes that the United States Food and Drug Administration had approved for use on a generic drug product’s brand-name equivalent. [read post]
25 Jun 2014, 2:00 pm by Maureen Johnston
Wyeth, LLC; and the plain language of the federal Food, Drug, and Cosmetic Act (“FDCA”)—that federal law does not preempt state tort claims predicated on allegations that a generic drug manufacturer violated the FDCA by failing to immediately implement or otherwise disseminate notice of labeling changes that the United States Food and Drug Administration had approved for use on a generic drug product's brand-name equivalent. [read post]